Brandes International ETF
Limited financial coverage for BINV.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The fund is an actively managed exchange-traded fund (“ETF”) that seeks to attain its investment objective by investing primarily in equity securities of foreign companies. The fund typically invests in foreign companies with market capitalizations (market value of publicly traded equity securities) greater than $5 billion at the time of purchase.
- CEO
- Michael D. Zarrillo
- IPO
- 2023
- Employees
- 78
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on BINV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $493.52M
- Div Yield
- 2.07%
- 52W High
- $46.05
- 52W Low
- $36.91
- 50D MA
- $43.68
- 200D MA
- $42.07
- Beta
- 0.38
- RSI (14)
- 62
- Avg Volume
- 39.52K
No earnings-call transcripts are available for BINV yet.
- Free Float
- 0.0%
- Shares Outstanding
- 10.88M
- Float Shares
- 0
of shares held by institutions
38 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Skopos Labs, Inc. | 155.34K | ▲ 18.64K |
| Principia Wealth Advisory, LLC | 303 | ▲ 76 |
| Cwm, LLC | 23 | 0 |
Our BINV coverage
Recent articles, reports, and earnings notes.
No research on BINV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BINV report →BioInvent International AB: Interim Report January - March 2026
accessnewswire.com · Apr 29
BioInvent International AB: Year-End Report January 1 - December 31, 2025
accessnewswire.com · Feb 26
BioInvent International AB: Year-End Report January 1 - December 31, 2024
accessnewswire.com · Feb 27
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma
accesswire.com · Jan 8
BINV: Brandes, The Iconic Value Stock Investor, In ETF Form
seekingalpha.com · Aug 1
BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO
accesswire.com · Jul 22
Panagora Asset Management Inc. Has $3.26 Million Stake in ACCO Brands Co. (NYSE:ACCO)
https://www.defenseworld.net · May 20
Why Goldman Sachs is helping its clients launch ETFs
cnbc.com · Apr 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.